JPWO2020117759A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020117759A5 JPWO2020117759A5 JP2021531100A JP2021531100A JPWO2020117759A5 JP WO2020117759 A5 JPWO2020117759 A5 JP WO2020117759A5 JP 2021531100 A JP2021531100 A JP 2021531100A JP 2021531100 A JP2021531100 A JP 2021531100A JP WO2020117759 A5 JPWO2020117759 A5 JP WO2020117759A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- pharmaceutically acceptable
- disease
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774482P | 2018-12-03 | 2018-12-03 | |
| US62/774,482 | 2018-12-03 | ||
| US201962938410P | 2019-11-21 | 2019-11-21 | |
| US62/938,410 | 2019-11-21 | ||
| PCT/US2019/064169 WO2020117759A1 (en) | 2018-12-03 | 2019-12-03 | Small molecule degraders of helios and methods of use |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022510313A JP2022510313A (ja) | 2022-01-26 |
| JPWO2020117759A5 true JPWO2020117759A5 (https=) | 2022-12-08 |
| JP2022510313A5 JP2022510313A5 (https=) | 2022-12-08 |
| JP7709378B2 JP7709378B2 (ja) | 2025-07-16 |
Family
ID=70974869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531100A Active JP7709378B2 (ja) | 2018-12-03 | 2019-12-03 | Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12227488B2 (https=) |
| EP (1) | EP3890736A4 (https=) |
| JP (1) | JP7709378B2 (https=) |
| KR (1) | KR20210098960A (https=) |
| CN (1) | CN113490495B (https=) |
| AU (1) | AU2019391016B2 (https=) |
| CA (1) | CA3119526A1 (https=) |
| WO (1) | WO2020117759A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7682181B2 (ja) | 2019-12-18 | 2025-05-23 | ノバルティス アーゲー | ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| AU2021275146A1 (en) * | 2020-05-21 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Piperidine-2,6-diones as small molecule degraders of Helios and methods of use |
| CN115916199A (zh) * | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| CN116669769A (zh) * | 2020-10-16 | 2023-08-29 | 达纳－法伯癌症研究所公司 | Helios的哌啶基小分子降解剂和使用方法 |
| CN113046391A (zh) * | 2021-03-22 | 2021-06-29 | 上海科技大学 | 一种crbn基因人源化动物肿瘤细胞模型的构建方法和用途 |
| PY2243958A (es) * | 2021-06-03 | 2023-01-20 | Novartis Ag | Derivados de 3–(5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026080794A1 (en) * | 2024-10-11 | 2026-04-16 | Bristol-Myers Squibb Company | Chemical compounds useful for degrading proteins |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| AU2002306596B2 (en) * | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| PE20110547A1 (es) | 2008-10-29 | 2011-08-04 | Celgene Corp | Compuestos de isoindolina con actividad anticancerigena |
| WO2016196580A1 (en) * | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| BR112019015484A2 (pt) * | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019079701A1 (en) | 2017-10-20 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2021275146A1 (en) * | 2020-05-21 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Piperidine-2,6-diones as small molecule degraders of Helios and methods of use |
-
2019
- 2019-12-03 US US17/298,823 patent/US12227488B2/en active Active
- 2019-12-03 EP EP19891781.7A patent/EP3890736A4/en active Pending
- 2019-12-03 JP JP2021531100A patent/JP7709378B2/ja active Active
- 2019-12-03 CA CA3119526A patent/CA3119526A1/en active Pending
- 2019-12-03 CN CN201980079725.5A patent/CN113490495B/zh active Active
- 2019-12-03 KR KR1020217013263A patent/KR20210098960A/ko active Pending
- 2019-12-03 WO PCT/US2019/064169 patent/WO2020117759A1/en not_active Ceased
- 2019-12-03 AU AU2019391016A patent/AU2019391016B2/en active Active
-
2025
- 2025-01-07 US US19/012,206 patent/US20250388562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020117759A5 (https=) | ||
| JP2024119812A5 (https=) | ||
| JP2021514001A5 (https=) | ||
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2006526646A5 (https=) | ||
| JP2006507265A5 (https=) | ||
| JP2020505395A5 (https=) | ||
| JP2018535967A5 (https=) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2024173998A5 (https=) | ||
| JP2006182786A5 (https=) | ||
| JP2006501201A5 (https=) | ||
| JPWO2021127561A5 (https=) | ||
| JP2021504314A5 (https=) | ||
| JP2019527724A5 (https=) | ||
| JP2011506566A5 (https=) | ||
| JP2011517697A5 (https=) | ||
| JP2014519507A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| JP2006503805A5 (https=) | ||
| JPWO2019165358A5 (https=) | ||
| JP2004523478A5 (https=) | ||
| JP2004525178A5 (https=) | ||
| JP2006514051A5 (https=) | ||
| JP2004536079A5 (https=) |